PatternsRadar
Sign in

DCALDishman Carbogen Amcis Limited

NSE
Full chart
153.57INR+2.07 (+1.37%)Close · 6 Oct 2026
14 Aug 2026Last results
HealthcareSector
Pharmaceuticals & BiotechnologyIndustry
₹2,408 CrMarket cap
149.0P/E (TTM)
50.7%Delivery

Filings & corporate actions

38 results filed
CSV
Next results · Q2 FY27
Expected 29 Oct 2026 – 14 Nov 2026
Estimate: filed 29–45 days after quarter end, last 5 times
Dividend
₹0.20 per share · last 12 Sept 2019
2026
  • 14 AugresultsResults · Q1 FY27 · consolidated and standalone-7.8%NSE
  • 21 JulshareholdingShareholding · 30 Jun 2026-0.3%NSE
  • 19 MayresultsResults · Q4 FY26 · consolidated and standalone+12.2%NSE
  • 21 AprshareholdingShareholding · 31 Mar 2026+1.2%NSE
  • 3 FebresultsResults · Q3 FY26 · consolidated and standalone-7.8%NSE
  • 21 JanshareholdingShareholding · 31 Dec 2025-4.8%NSE

Reaction to results · all yearsrose on day 0 in 15 of 40 CSV

QuarterFiledDay 0+5D+20DRel vol
Q1 FY2714 Aug 2026-7.8%-9.1%-14.4%12.5×
Q4 FY2619 May 2026+12.2%+5.0%-9.7%18.7×
Q3 FY263 Feb 2026-7.8%-8.5%-28.1%4.3×
Q2 FY264 Nov 2025-10.0%-17.4%-23.2%3.6×
Q1 FY2612 Aug 2025+5.0%+11.1%+8.6%0.5×
Q4 FY2521 May 2025+11.5%+20.8%+9.5%23.8×
Q3 FY2513 Feb 2025-11.1%-3.3%-4.7%2.0×
Q2 FY2514 Nov 2024+7.0%+12.0%+34.7%7.8×
Q1 FY2514 Aug 2024+2.0%+11.5%+16.2%0.4×
Q4 FY2431 May 2024-4.3%+1.7%+5.5%1.9×
Q3 FY2415 Feb 2024-0.1%+19.6%+8.9%2.4×
Q2 FY249 Nov 2023-3.1%+0.2%-3.6%1.4×
Q1 FY2410 Aug 2023-0.1%-6.2%+0.4%1.8×
Q4 FY2324 May 2023+1.4%+5.7%+24.4%0.8×
Q3 FY2311 Feb 2023+13.5%+26.2%+48.7%29.2×
Q2 FY2312 Nov 2022+6.2%-5.6%-8.2%2.6×
Q1 FY2310 Aug 2022+0.3%+4.5%+0.5%1.3×
Q4 FY2211 May 2022-22.6%-20.9%-10.7%5.7×
Q3 FY224 Feb 2022-4.3%-12.5%-21.8%0.9×
Q2 FY2229 Oct 2021-2.9%+1.7%+12.9%0.5×
Q1 FY2213 Aug 20210.0%-17.2%+2.0%0.9×
Q4 FY2112 May 2021+1.9%+17.8%+30.0%1.0×
Q3 FY2112 Feb 2021-0.1%-3.7%+0.1%0.6×
Q2 FY2113 Nov 2020-2.0%+9.7%+20.8%2.3×
Q1 FY219 Sept 2020-3.7%-0.3%-0.2%2.1×
Q4 FY204 Jun 2020-2.2%+67.0%+72.5%4.7×
Q3 FY2024 Jan 2020-2.3%-10.6%+5.2%1.0×
Q2 FY2024 Oct 2019-8.0%-17.6%-6.4%3.1×
Q1 FY2014 Aug 2019-5.5%-15.5%-7.8%0.5×
Q4 FY1916 May 2019-4.3%+1.0%+8.8%2.1×
Q3 FY1924 Jan 2019-1.6%-7.0%-14.9%1.2×
Q2 FY1923 Nov 2018-0.6%-3.4%-5.4%0.6×
Q1 FY192 Aug 2018+1.1%+3.2%+19.3%2.6×
Q4 FY1725 May 2018+1.8%-4.8%-10.1%1.0×
Q4 FY1825 May 2018+1.8%-4.8%-10.1%1.0×
Q3 FY1830 Jan 2018+0.5%-7.3%-11.3%0.6×
Q3 FY1730 Jan 2018+0.5%-7.3%-11.3%0.6×
Q2 FY1713 Nov 2017-4.4%-7.5%-1.6%1.3×
Q1 FY1813 Nov 2017-4.4%-7.5%-1.6%1.3×
Q2 FY1813 Nov 2017-4.4%-7.5%-1.6%1.3×
Average-1.3%+0.3%+3.1%

Close-to-close from the session before the filing could trade. Day 0 is the first session after it.

Growth · Q1 FY27

CSV
Revenue YoY-4.3%
Profit YoY-347.2%
Interest cost YoY-1.0%
Revenue QoQ-20.4%
Profit QoQ-366.2%
CAGR2Y3Y4Y5Y6Y7Y
Revenue+9.6%+3.8%+8.0%+7.9%+6.4%+4.7%
Profit——+28.3%—-28.9%-30.5%

Key data

CSV
Open151.70
Day range151.70 – 155.89
52-week range128.50 – 306.00
From 52w high-49.8%
RSI (14)33.2
ATR (14)6.46
Volume1.71L
Avg volume (20D)2.23L
Rel volume0.77×
Volatility (1Y)53.1%
Turnover₹2.6Cr
SMA 50 / 200175.43 / 189.40

Delivery percentage

Latest · 6 Oct 202650.7%
20-day avg52.7%
1-year avg50.8%
Percentile (own history)63rd
Range10.0–100.0%
Sessions1,731

Over the last 20 sessions DCAL settled 52.7% of its traded quantity, which is above average for an NSE equity. That is in line with its own one-year average of 50.8%. The latest session ranks higher than 63% of the 1,731 sessions on record for it.

What delivery percentage measuresScan the whole market on delivery

IndustryPharmaceuticals
PeersDIVISLABLAURUSLABSSUNPHARMAWOCKPHARMADRREDDYMOREPENLAB

Performance returns

CSV
1D1W1M3M6M1Y
Price+1.37%-6.51%-13.23%-22.30%+4.12%-45.40%

Valuation

CSV
Market cap₹2,408 Cr
P/E (TTM)149.0
EPS (TTM)1.03
Shares outstanding15.68Cr
Listed21 Sept 2017

Ownership

CSV
Promoter59.32%
Promoter Δ QoQ0.00 pp
Public40.68%
FII6.86%
DII2.07%
Pledged0.00%

Quarterly results · consolidated

CSV
Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue (₹ Cr)652.7719.8851.4677.6
YoY chg-17.3%+5.5%+18.9%-4.3%
Net profit (₹ Cr)65.3(13.0)21.7(57.9)
YoY chg+97.2%-380.1%-49.5%-347.2%
Net margin10.0%-1.8%2.6%-8.5%
EPS4.16-0.831.39-3.69

Shareholding over time

CSV

By quarter

30 Jun 2026 · promoter 59.32% · public 40.68%
30 Sept 2021: promoter 59.32%31 Dec 2021: promoter 59.32%31 Mar 2022: promoter 59.32%30 Jun 2022: promoter 59.32%30 Sept 2022: promoter 59.32%31 Dec 2022: promoter 59.32%31 Mar 2023: promoter 59.32%30 Jun 2023: promoter 59.32%30 Sept 2023: promoter 59.32%31 Dec 2023: promoter 59.32%31 Mar 2024: promoter 59.32%30 Jun 2024: promoter 59.32%30 Sept 2024: promoter 59.32%31 Dec 2024: promoter 59.32%31 Mar 2025: promoter 59.32%30 Jun 2025: promoter 59.32%30 Sept 2025: promoter 59.32%31 Dec 2025: promoter 59.32%31 Mar 2026: promoter 59.32%30 Jun 2026: promoter 59.32%
2021-092026-06
  • Promoter
  • Public and others
Promoter
59.32%
Public
40.68%
Promoter change
0.00 pp
Filed
21 Jul 2026
FII
6.86%
DII
2.07%
Promoter pledged
0.00%

Promoter and public shares of total equity, from the pattern filed each quarter. Institutional and pledge figures come from a separate filing stage whose backfill is still running, so they are absent for almost every instrument rather than zero.

Financials · quarterly statement

CSV
₹ crore, as filed
 Q2 FY24Q3 FY24Q4 FY24AQ1 FY25Q2 FY25Q3 FY25Q4 FY25AQ1 FY26Q2 FY26Q3 FY26Q4 FY26AQ1 FY27
Revenue from operations586.6651.1654.7523.8789.0682.3716.3708.1652.7719.8851.4677.6
Other income8.56.17.21.46.75.68.024.88.16.716.418.2
Total income595.1657.1661.9525.2795.7688.0724.3732.8660.8726.5867.8695.8
Total expenses628.3723.4708.0597.3750.6663.0684.9691.5630.2736.9820.5745.3
└ Finance costs27.533.131.031.936.648.842.142.842.345.843.337.1
└ Depreciation75.080.485.070.672.172.079.181.484.184.488.890.7
Profit before tax(36.3)(66.3)(49.2)(77.6)42.127.127.738.730.5(10.4)46.1(51.2)
Tax expense4.6(6.7)20.70.09.022.4(15.4)15.3(34.7)2.524.46.7
Net profit(40.9)(59.6)(69.9)(77.6)33.14.643.123.465.3(13.0)21.7(57.9)
EPS-2.61-3.80-4.46-4.952.110.302.751.494.16-0.831.39-3.69
Net margin-6.97%-9.16%-10.68%-14.81%4.19%0.68%6.02%3.31%10.00%-1.80%2.55%-8.54%
PBT margin-6.18%-10.18%-7.51%-14.81%5.34%3.96%3.87%5.46%4.68%-1.45%5.42%-7.56%
Tax rate————21.44%82.88%-55.56%39.46%-113.72%—52.87%—

A audited · R restated by a later filing · negatives in parentheses. EPS and the share count are restated onto the same split-adjusted basis as the price chart, so they can be read against it; every rupee figure is exactly as filed. A quarterly filing carries a profit and loss only — there is no balance sheet behind it, and so no debt, cash flow or return-on-capital figure here. Latest filed 14 Aug 2026.

DCAL at a glance

  • DCAL closed at ₹153.57 on 6 Oct 2026, +1.37% on the day, -45.4% over one year, 49.8% below its 52-week high of ₹306.
  • Delivery was 50.7% of traded quantity on 6 Oct 2026, the 63rd percentile of its own 1,731 sessions with a reading (20-session average 52.7%, 1-year average 50.8%).
  • Market capitalisation is ₹2,408 crore at a trailing P/E of 149.0 (trailing EPS ₹1.03).
  • Q1 FY27 results (consolidated, filed 14 Aug 2026): revenue ₹678 crore (-4.3% year on year), net profit ₹-58 crore (-347.2%); the price moved -7.8% on the first session after.
  • Promoters held 59.32% at 30 Jun 2026, unchanged on the previous filing.
  • Q2 FY27 results are expected between 29 Oct 2026 and 14 Nov 2026, going by past filing dates — an estimate, not an announcement.

About

CSV
Macro sectorHealthcare
Basic industryPharmaceuticals
ISININE385W01011
SeriesEQ
Listed21 Sept 2017
History from21 Sept 2017
Sessions2,236

Prices are adjusted for splits and bonuses. Delivery figures come from NSE’s daily reports and are unavailable for older sessions. Sourced from the eod2 dataset, last updated 6 Oct 2026.

More in Pharmaceuticals & Biotechnology

CSV

All Pharmaceuticals & Biotechnology stocks on the NSEAll Healthcare stocks on the NSE